Table of Contents
I. Call for Application for Early Career Investigator Showcase (ECIS) Award
Due September 10, 2021, 5:00 PM EDT
II. RFA-DA-22-031 HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 - Clinical Trial Not Allowed) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-031.html Application due date: October 19, 2021 due by 5:00 PM local time of applicant organization.
III. RFA-DA-22-032 HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 - Clinical Trial Not Allowed) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-032.html Application due date: October 19, 2021 due by 5:00 PM local time of applicant organization.
IV. NOT-DA-20-030 Notice of Special Interest (NOSI): Human Molecular Genetics of Substance Use Disorders https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-030.html Application Due Dates: Standard Due Dates Apply.
---------
I. Call for Application for Early Career Investigator Showcase (ECIS) Award
Due September 10, 2021, 5:00 PM EDT
The 2021 NIDA-NIAAA Mini-Convention is now soliciting applications for the Early Career Investigator Showcase (ECIS) award. Applicants should be trainees or junior investigators who meet the definition of a NIH New Investigator/Early Stage Investigator [NI/ESI] of being within 10 years of completing a terminal research degree or medical residency [http://grants.nih.gov/grants/new_investigators/]. Eight (8) individuals will be selected for this symposium. Individuals selected for ECIS will be chosen for the quality of their research and its relevance to the missions of NIDA or NIAAA, or to the themes of the scientific sessions of the Mini-Convention. ECIS participants are expected to prepare both a virtual poster presentation of their research that will be available to attendees during the Mini-Convention and an 8-minute oral presentation that briefly describes the research.
To apply, please complete the application form, include your Curriculum Vitae/Resume and list of publications, and send via email (to ECIS.Abstracts@seiservices.com) by Friday, September 10, 2021 5:00 PM (EDT). To consider your application, you must select only one Institute on the form. Abstracts accepted for the 2021 SfN Virtual Meeting may be submitted for presentation at ECIS. All applicants will be notified of the status of their submission by Friday, October 8, 2021. For additional information, please contact: for NIDA [Anne Tsai, stsai@nih.gov] or for NIAAA [John Matochik, jmatochi@mail.nih.gov].
---------------
II. RFA-DA-22-031 HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R01 - Clinical Trial Not Allowed) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-031.html Application due date: October 19, 2021 due by 5:00 PM local time of applicant organization.
This funding opportunity announcement aims to support research focusing on the identification of druggable new targets and discovery of optimizable probes for development of safe and efficacious medications to prevent or treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. This announcement is specifically focused on identification of novel targets and early preclinical development of small molecules and biologics. Emphasis is on the identification of drug targets and validation through development of probe molecules to modulate those targets.
---------------------
III. RFA-DA-22-032 HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose (R21 - Clinical Trial Not Allowed) https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-032.html Application due date: October 19, 2021 due by 5:00 PM local time of applicant organization.
This funding opportunity announcement aims to support research focusing on the identification of druggable new targets and discovery of optimizable probes for development of safe and efficacious medications to prevent or treat opioid use disorders (OUDs), opioid overdose, and opioid-polysubstance use comorbidities. This announcement is specifically focused on identification of novel targets and early preclinical development of small molecules and biologics. Emphasis is on the identification of drug targets and validation through development of probe molecules to modulate those targets.
--------------
IV. NOT-DA-20-030 Notice of Special Interest (NOSI): Human Molecular Genetics of Substance Use Disorders https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-030.html Application Due Dates: Standard Due Dates Apply.
This Notice encourages applications for research projects that identify, validate and/or functionally characterize loci, genetic variations and haplotypes that are associated with vulnerability to addiction and that potentially inform the likelihood of responsiveness to treatment. Data may be collected from the general population, special populations, recent admixed populations, and/or electronic medical records (EMR). Secondary data analysis of data collected from the general population, special populations, recent admixed populations, and/or animal models is also appropriate for this notice. Investigators are encouraged to include functional characterization, gene x gene interactions, gene x environment interactions, and gene x environment x development interactions.
-------------------
The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-
